Interference of daratumumab with pretransfusion testing, mimicking a high-titer, low avidity like antibody

Daratumumab is a monoclonal immunoglobulin against CD38 and has been approved for treating patients with refractory multiple myeloma. The presence of daratumumab in the sera can interfere with pretransfusion testing due to the weakly expression of CD38 on red cells. The reactivity could be mistaken...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Mei-Hwa, Liu, Fei-Yun, Wang, Hsiu-Mien, Cho, Hsin-Ching, Lo, Shyh-Chyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613434/
https://www.ncbi.nlm.nih.gov/pubmed/28970695
http://dx.doi.org/10.4103/0973-6247.214358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613434/
https://www.ncbi.nlm.nih.gov/pubmed/28970695
http://dx.doi.org/10.4103/0973-6247.214358

Ejemplares similares